Date
- 2026 (24)
- 2025 (70)
- 2024 (100)
- 2023 (82)
- 2022 (63)
- 2021 (121)
- 2020 (150)
- 2019 (52)
- 2018 (53)
- 2017 (52)
- 2016 (4)
- 2015 (37)
- 2014 (22)
- 2013 (23)
- 2012 (12)
- 2011 (51)
- 2010 (45)
- 2009 (32)
- 2008 (27)
- 2007 (17)
- 2006 (21)
- 2005 (51)
- 2004 (12)
- 2003 (10)
- 2002 (9)
- 2001 (5)
- 2000 (5)
- 1999 (5)
- 1998 (9)
- 1997 (3)
- 1991 (3)
Sponsor content
1170 result(s) found, displaying 41 to 50
-
Prescription medicine registrationActive ingredients: rivaroxaban.
-
Australian Public Assessment Report (AusPAR)Afqlir; Enzeevu (aflibercept) 2 mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (wet AMD), CRVO, BRVO, DMEmyopic and CNV.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENZEEVU aflibercept 40 mg/mL solution for intravitreal injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFQLIR aflibercept 40 mg/mL solution for intravitreal injection vial with needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENZEEVU aflibercept 40 mg/mL solution for intravitreal injection vial with needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFQLIR aflibercept 40 mg/mL solution for intravitreal injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHYLPHENIDATE SANDOZ XR methylphenidate hydrochloride 27 mg modified release tablet, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHYLPHENIDATE SANDOZ XR methylphenidate hydrochloride 18 mg modified release tablet, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHYLPHENIDATE SANDOZ XR methylphenidate hydrochloride 54 mg modified release tablet, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHYLPHENIDATE SANDOZ XR methylphenidate hydrochloride 36 mg modified release tablet, bottle.